Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Maher Issa"'
Autor:
Thomas Bieber, Norito Katoh, Eric L. Simpson, Marjolein de Bruin-Weller, Diamant Thaçi, Antonio Torrelo, Angelina Sontag, Susanne Grond, Maher Issa, Xiaoyu Lu, Tracy Cardillo, Katrin Holzwarth, Jacob P. Thyssen
Publikováno v:
Journal of Dermatological Treatment, Vol 34, Iss 1 (2023)
Background Baricitinib, a selective Janus kinase (JAK)1/JAK2 inhibitor, is approved for treatment of moderate-to-severe atopic dermatitis (AD) in adults. Objectives We report integrated baricitinib safety data in patients with up to 3.9-years exposur
Externí odkaz:
https://doaj.org/article/ca9ed6e40be942ef9798f73046c71ec1
Autor:
Josef S Smolen, Yoshiya Tanaka, Michelle Petri, Inmaculada de la Torre, Thomas Dörner, Gabriella Meszaros, Hong Zhang, Maher Issa, Eric Morand, Christina Dickson, Maria Silk
Publikováno v:
RMD Open, Vol 9, Iss 3 (2023)
Objectives To assess the safety of the oral Janus kinase inhibitor baricitinib in adult patients with systemic lupus erythematosus (SLE) receiving stable background therapy. Topics of special interest included infections and cardiovascular and thromb
Externí odkaz:
https://doaj.org/article/b0fa1e1523c24778a50a0ff1915f0a24
Autor:
Wael Ben Mbarek, Maher Issa, Victoria Salvadó, Lluisa Escoda, Mohamed Khitouni, Joan-Josep Suñol
Publikováno v:
Materials, Vol 16, Iss 24, p 7612 (2023)
In this study, the efficiency of mechanically alloyed Fe80Si10B10 in degrading basic red 46 azo dye is investigated. Moreover, the influences of different parameters, such as pH and time, on the elimination of the aromatic derivatives obtained as by-
Externí odkaz:
https://doaj.org/article/01e042a3dbac44ba9ad297339e9eb5a0
Autor:
Kevin L. Winthrop, Clifton O. Bingham, Wendy J. Komocsar, John Bradley, Maher Issa, Rena Klar, Cynthia E. Kartman
Publikováno v:
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-10 (2019)
Abstract Background Clinical guidelines recommend pneumococcal and tetanus vaccinations in patients with rheumatoid arthritis (RA). Baricitinib is an oral, selective Janus kinase (JAK) 1/JAK 2 inhibitor and is approved for the treatment of moderately
Externí odkaz:
https://doaj.org/article/fb4179395d57473eb50cfb25ed303174
Autor:
Inmaculada de la Torre, Masayoshi Harigai, Joel M Kremer, Edward C Keystone, Maher Issa, Christina Dickson, Josh Rancourt, Thomas Melby, Yoshitaka Isaka, Anabela Cardoso, Chadi Saifan
Publikováno v:
RMD Open, Vol 6, Iss 3 (2020)
Objective To characterise changes in selected haematological parameters following once-daily oral baricitinib dosing.Methods Data were pooled from eight randomised clinical trials (four phase 3, three phase 2, one phase 1b) and one long-term extensio
Externí odkaz:
https://doaj.org/article/a4233ce845114923aee5548ee591ccb3
Autor:
Thomas Bieber, Eugen Feist, Alan D. Irvine, Masayoshi Harigai, Ewa Haladyj, Susan Ball, Walter Deberdt, Maher Issa, Susanne Grond, Peter C. Taylor
Baricitinib is an oral, selective inhibitor of Janus kinase (JAK)1/JAK2 that transiently and reversibly inhibits many proinflammatory cytokines. This mechanism is a key mediator in a number of chronic inflammatory diseases; accordingly, baricitinib h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6347671bc7a759e0f22708ead2482f6
https://doi.org/10.1007/s12325-022-02281-4
https://doi.org/10.1007/s12325-022-02281-4
Autor:
Andreas Wollenberg, Leon Kircik, Eric Simpson, Dennis Brinker, Norito Katoh, Maria Jose Rueda, Maher Issa, Fan Yang, Meghan Feely, Andrew Alexis
Publikováno v:
Dermatitis®.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa37afd23d301e61fdb82bc761743f69
https://doi.org/10.1089/derm.2022.0027
https://doi.org/10.1089/derm.2022.0027
Autor:
Edward Lain, Fabio P. Nunes, Dennis Brinker, Catherine Maari, Maher Issa, Eric L. Simpson, Tracy Cardillo, Katrin Holzwarth, Jonathan I. Silverberg, Brett A. King
Publikováno v:
American Journal of Clinical Dermatology
Background Baricitinib, a selective Janus kinase 1/Janus kinase 2 inhibitor, is indicated in the European Union and Japan for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy. Objective The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7be42197ba267ec6e760c1d53e777c73
https://doi.org/10.1007/s40257-021-00602-x
https://doi.org/10.1007/s40257-021-00602-x
Autor:
T. Bieber, Margaret Gamalo, Fabio P. Nunes, Norito Katoh, Diamant Thaçi, Maher Issa, Kristian Reich, Dennis Brinker, Jamie Weisman, Eric L. Simpson, E. Riedl, Antonio Torrelo, M S de Bruin-Weller, Jacob P. Thyssen, Robert Bissonnette, Katrin Holzwarth, Melinda Gooderham, Jonathan Janes
Publikováno v:
Journal of the European Academy of Dermatology and Venereology. 35:476-485
Background Janus kinase (JAK) inhibition is a new mode of action in atopic dermatitis (AD); clarity about drug class safety considerations in the context of AD is important. Baricitinib, an oral, reversible, selective inhibitor of JAK1/JAK2, is in la
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70be05fd68d8b28351af8405ac359cb2
https://doi.org/10.1111/jdv.16948
https://doi.org/10.1111/jdv.16948
Autor:
Dennis Brinker, Josef S Smolen, Mo Daojun, Terence Rooney, Anabela Cardoso, Wen Shuo Wu, Tsutomu Takeuchi, Jinglin Zhong, Chadi Saifan, Kevin L. Winthrop, Mark C. Genovese, Gerd R Burmester, Maher Issa
Publikováno v:
The Lancet Rheumatology. 2:e347-e357
Summary Background Baricitinib is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK2, approved for the treatment of patients with active rheumatoid arthritis. Because baricitinib, like other disease-modifying antirheumatic drugs, is used ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5eb80bf2508e4b89da272a8cfb790d1d
https://doi.org/10.1016/s2665-9913(20)30032-1
https://doi.org/10.1016/s2665-9913(20)30032-1